CD4 and graft versus host disease: IL-18 treatment in vivo accelerated GVHD lethality in mice engrafted with PBMC plus enriched CD4+CD25− effector cells, or with PBMC plus ex vivo expanded CD4+25+ cells (Fig. 6A and B).